No CrossRef data available.
Article contents
Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals
Published online by Cambridge University Press: 06 August 2024
Abstract
Background
Clozapine-induced inflammation, such as myocarditis and pneumonia, can occur during initial titration and can be fatal. Fever is often the first sign of severe inflammation, and early detection and prevention are essential. Few studies have investigated the effects of clozapine titration speed and concomitant medication use on the risk of clozapine-induced inflammation.
Aims
We evaluated the risk factors for clozapine-associated fever, including titration speed, concomitant medication use, gender and obesity, and their impact on the risk of fever and the fever onset date.
Method
We conducted a case-control study. The medical records of 539 Japanese participants with treatment-resistant schizophrenia at 21 hospitals in Japan who received clozapine for the first time between 2010 and 2022 were retrospectively investigated. Of these, 512 individuals were included in the analysis. Individuals were divided into three groups according to the titration rate recommended by international guidelines for East Asians: the faster titration group, the slower titration group and the ultra-slower titration group. The use of concomitant medications (such as antipsychotics, mood stabilisers, hypnotics and anxiolytics) at clozapine initiation was comprehensively investigated. Logistic regression analysis was performed to identify the explanatory variables for the risk of a fever of 37.5°C or higher lasting at least 2 days.
Results
Fever risk significantly increased with faster titration, male gender and concomitant use of valproic acid or quetiapine. No increased fever risk was detected with the use of other concomitant drugs, such as olanzapine, lithium or orexin receptor antagonists. Fever onset occurred significantly earlier with faster titration. Multivariate analysis identified obesity as being a factor that accelerated fever onset.
Conclusion
A faster titration speed and concomitant treatment with valproic acid and quetiapine at clozapine initiation increased the risk of clozapine-associated fever. Clinicians should titrate clozapine with caution and consider both the titration speed and concomitant medications.
- Type
- Original Article
- Information
- Copyright
- Copyright © The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists
References
Oloyede, E, Taylor, D, MacCabe, J. International variation in clozapine hematologic monitoring - a call for action. JAMA Psychiatry 2023; 80: 535–6.CrossRefGoogle ScholarPubMed
Verdoux, H, Quiles, C, de Leon, J. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. Schizophr Res 2019; 211: 1–9.CrossRefGoogle ScholarPubMed
De Las Cuevas, C, Sanz, EJ, Ruan, CJ, de Leon, J. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: focus on reports from various countries. Rev Psiquiatr Salud Ment (English edn) 2021; 15: 238–50.Google Scholar
de Filippis, R, Kane, JM, Kuzo, N, Spina, E, De Sarro, G, de Leon, J, et al. Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. Eur Neuropsychopharmacol 2022; 60: 25–37.CrossRefGoogle ScholarPubMed
de Leon, J, Schoretsanitis, G, Smith, RL, Molden, E, Solismaa, A, Seppala, N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 2022; 55: 73–86.Google ScholarPubMed
de Leon, J, Ruan, CJ, Schoretsanitis, G, Rohde, C, Yagcioglu, EA, Baptista, T, et al. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine. Gen Psychiatr 2022; 35: e100773.CrossRefGoogle ScholarPubMed
Yasui-Furukori, N, Otsuka, Y, de Leon, J. Japanese patients need slower, personalized clozapine titrations: a comment on the case described by Kikuchi et al. Psychiatry Clin Neurosci Rep 2023; 2: e70.Google ScholarPubMed
Reeves, S, Bertrand, J, Obee, SJ, Hunter, S, Howard, R, Flanagan, RJ. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol 2024; 90: 135–45.CrossRefGoogle ScholarPubMed
Kikuchi, Y, Komatsu, H, Otsuka, Y, Ito, F, Kanahara, N, Tanifuji, H, et al. Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals. Schizophr Res 2024; 268: 98–106.CrossRefGoogle Scholar
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, Topliss, DJ, Wolfe, R, McNeil, JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012; 141: 173–8.CrossRefGoogle ScholarPubMed
Pui-yin Chung, J, Shiu-yin Chong, C, Chung, KF, Lai-wah Dunn, E, Wai-nang Tang, O, Chan, WF. The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53: 857–62.CrossRefGoogle Scholar
Vickers, M, Ramineni, V, Malacova, E, Eriksson, L, McMahon, K, Moudgil, V, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis. Acta Psychiatr Scand 2022; 145: 442–55.CrossRefGoogle ScholarPubMed
Kikuchi, Y, Komatsu, H, Otsuka, Y, Ito, F, Yada, Y, Tanifuji, H, et al. Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia. Psychiatry Res 2024; 334: 115810.CrossRefGoogle ScholarPubMed
Kang, N, Kim, SH, Kim, J, Kim, S, Jang, J, Yoon, H, et al. Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital. Schizophr Res 2024; 268: 131–7.CrossRefGoogle Scholar
Kang, N, Kim, SH, Kim, J, Kim, S, Jang, J, Yoon, H, et al. Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital. Schizophr Res 2024; 268: 107–13.CrossRefGoogle Scholar
Schoretsanitis, G, de Leon, J. Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s). J Clin Psychiatry 2022; 83: 22ac14500.CrossRefGoogle ScholarPubMed
De Las Cuevas, C, Sanz, EJ, Rohde, C, de Leon, J. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Rev Clin Pharmacol 2022; 15: 65–78.CrossRefGoogle Scholar
Clapham, E, Reutfors, J, Linder, M, Brandt, L, Sundstrom, J, Boden, R. The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: a population-based cohort study. Psychiatry Res 2023; 326: 115336.CrossRefGoogle ScholarPubMed
De Las Cuevas, C, Arrojo-Romero, M, Ruan, C-J, Schoretsanitis, G, Sanz, EJ, de Leon, J. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review. Expert Opin Drug Metabol Toxicol 2023; 18: 715–27.CrossRefGoogle Scholar
Nachmani Major, N, Dawson, BHJL, Clark, SR. Implementation and outcomes of a clozapine-associated myocarditis screening program in a region of South Australia – lessons learned. J Clin Psychopharmacol 2020; 40: 250–8.CrossRefGoogle Scholar
Kikuchi, Y, Sato, T, Murakami, K, Otsuka, T, Machida, T, Yoshikawa, K, et al. Concomitant use of clozapine and suvorexant doubled clozapine plasma levels: a case report. J Clin Psychopharmacol 2024; 44(2): 185–7.CrossRefGoogle ScholarPubMed
Watanabe, K, Misaka, S, Kanno-Nozaki, K, Chiyoda, T, Suzuki, Y, Sato, A, et al. Effect of lemborexant on pharmacokinetics of clozapine: a potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4. Br J Clin Pharmacol 2024; 90: 354–9.CrossRefGoogle ScholarPubMed
Kikuchi, Y, Yada, Y, Otsuka, Y, Ito, F, Tanifuji, H, Komatsu, H, et al. Slower clozapine titration is associated with delayed onset of clozapine-induced fever among Japanese patients with schizophrenia. Schizophrenia 2023; 9: 82.CrossRefGoogle ScholarPubMed
Inada, T, Inagaki, A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015; 69: 440–7.CrossRefGoogle ScholarPubMed
de Leon, J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit 2020; 42: 159–61.CrossRefGoogle ScholarPubMed
Ertuğrul, A, Anıl Yağcıoğlu, AE, Ağaoğlu, E, Karakaşlı, AA, Ak, S, Yazıcı, MK, et al. Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: a re-analysis of a Turkish case series. Rev Psiquiatr Salud Ment (English edn) 2022; 15: 281–6.Google ScholarPubMed
Koenig, M, McCollum, B, Spivey, JK, Coleman, JK, Shelton, C, Cotes, RO, et al. Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. Neuropsychopharmacol Hung 2022; 24: 29–41.Google Scholar
Wollmann, BM, Haugen, AG, Smith, RL, Molden, E. Novel identification of cysteinyl derivatives of toxic clozapine nitrenium ions and the effect of valproic acid on metabolite formation: a study using reprocessed high-resolution mass spectra of analyzed therapeutic drug monitoring samples. Ther Drug Monit 2024; 46: 265–9.CrossRefGoogle ScholarPubMed
Ochi, S, Tagata, H, Hasegawa, N, Yasui-Furukori, N, Iga, JI, Kashiwagi, H, et al. Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: a real-world nationwide study. Int J Neuropsychopharmacol 2022; 25: 818–26.CrossRefGoogle ScholarPubMed
Kishi, T, Nishida, M, Koebis, M, Taninaga, T, Muramoto, K, Kubota, N, et al. Evidence-based insomnia treatment strategy using novel orexin antagonists: a review. Neuropsychopharmacol Rep 2021; 41: 450–8.CrossRefGoogle ScholarPubMed
Usui, K, Kikuchi, D, Otsuka, N, Miyagi, K, Ouchi, R, Watanabe, T, et al. Hypnotic prescriptions in Japan may be shifting from benzodiazepine receptor agonists to other types of hypnotics, melatonin receptor agonists, and orexin receptor antagonists. Psychiatry Clin Neurosci Rep 2023; 2: e113.Google ScholarPubMed
Kikuchi, Y, Tanifuji, H, Ueno, S, Onuma, Y, Goto, M, Ishihara, M, et al. Patterns of C-reactive protein trends during clozapine titration and the onset of clozapine-induced inflammation: a case series of weekly and daily C-reactive protein monitoring. Front Psychiatry 2024; 15: 1366621.CrossRefGoogle ScholarPubMed
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, Topliss, DJ, McNeil, JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458–65.CrossRefGoogle Scholar
Taylor, D, Cahill, C, Wallang, P, Millard, L, Cela, LR, Breen, KC. Predicting clozapine dose required to achieve a therapeutic plasma concentration - a comparison of a population algorithm and three algorithms based on gene variant models. J Psychopharmacol 2023; 37: 1030–9.CrossRefGoogle ScholarPubMed
Kikuchi et al. supplementary material 1
Kikuchi et al. supplementary material
File
19.8 KB
Kikuchi et al. supplementary material 2
Kikuchi et al. supplementary material
File
20.3 KB
eLetters
No eLetters have been published for this article.